^
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (NCT05564377)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/07/2023
    Primary completion :
    07/01/2030
    Completion :
    07/01/2030
    BRAF
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • Tasigna (nilotinib) • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical
    Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (ASC4MORE) (NCT03578367)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    11/22/2018
    Primary completion :
    11/08/2021
    Completion :
    02/27/2025
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START) (NCT05456191)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/21/2022
    Primary completion :
    03/17/2025
    Completion :
    07/07/2031
    ABL1
    |
    Tasigna (nilotinib) • Scemblix (asciminib)
    Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (NCT01698905)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/20/2012
    Primary completion :
    11/26/2015
    Completion :
    01/19/2025
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTFreedom) (NCT01784068)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/04/2013
    Primary completion :
    05/31/2016
    Completion :
    01/24/2025
    ABL1 • BCR
    |
    BCR-ABL1 E255K • BCR-ABL1 Y253H
    |
    Tasigna (nilotinib)
    Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia (PInNACLe) (NCT02001818)
    Phase 2
    Australasian Leukaemia and Lymphoma Group
    Completed
    Last update posted :
    08/06/2024
    Initiation :
    04/11/2014
    Primary completion :
    01/07/2022
    Completion :
    01/07/2022
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib) • ViraferonPeg (peginterferon-α-2b)
    Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel (NCT04449549)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    08/24/2020
    Primary completion :
    04/02/2025
    Completion :
    04/08/2025
    NF1
    |
    paclitaxel • Tasigna (nilotinib)
    Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/10/2024
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    PDGFRA
    |
    PDGFRA D842V • KIT L576P • KIT K642E • KIT V559 • KIT V559A • KIT W557
    |
    paclitaxel • Tasigna (nilotinib)
    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib (NCT01746836)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    01/17/2013
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    BCR
    |
    dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib)
    A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (ASC4FIRST) (NCT04971226)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/03/2024
    Initiation :
    10/06/2021
    Primary completion :
    11/28/2023
    Completion :
    01/18/2028
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Bosulif (bosutinib) • Scemblix (asciminib)
    De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) (NCT03874858)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    04/22/2024
    Initiation :
    03/22/2019
    Primary completion :
    07/31/2026
    Completion :
    12/31/2026
    ABL1 • BCR • TFRC
    |
    Tasigna (nilotinib) • Scemblix (asciminib)
    Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation (NCT04838041)
    Phase 2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    11/11/2021
    Primary completion :
    06/01/2028
    Completion :
    07/01/2029
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT05143840)
    Phase 2
    Augusta University
    Recruiting
    Last update posted :
    03/26/2024
    Initiation :
    04/22/2022
    Primary completion :
    02/01/2025
    Completion :
    02/01/2027
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL (CABL001X2101) (NCT02081378)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    03/18/2024
    Initiation :
    04/24/2014
    Primary completion :
    06/03/2021
    Completion :
    03/14/2023
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN) (NCT04626024)
    Phase 2
    Baylor College of Medicine
    Recruiting
    Last update posted :
    12/13/2023
    Initiation :
    12/22/2020
    Primary completion :
    11/15/2025
    Completion :
    11/15/2025
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Bosulif (bosutinib)
    2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT) (NCT02917720)
    Phase 2
    European LeukemiaNet
    Active, not recruiting
    Last update posted :
    12/11/2023
    Initiation :
    09/01/2016
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease (ECOG-ACRIN EA9171) (NCT03516279)
    Phase 2
    ECOG-ACRIN Cancer Research Group
    Recruiting
    Last update posted :
    11/28/2023
    Initiation :
    06/26/2019
    Primary completion :
    08/31/2028
    Completion :
    08/31/2031
    ABL1 • BCR • CD4
    |
    Keytruda (pembrolizumab) • dasatinib • imatinib • Tasigna (nilotinib)
    Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (NCT03654768)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    11/13/2023
    Initiation :
    10/24/2018
    Primary completion :
    07/01/2024
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    dasatinib • imatinib • Jakafi (ruxolitinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
    Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (HS-2020-07SZ) (NCT04739826)
    Phase N/A
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/03/2023
    Initiation :
    09/25/2020
    Primary completion :
    01/01/2025
    Completion :
    12/01/2025
    ABL1 • BCR
    |
    Tasigna (nilotinib) • Hansoh Xinfu (flumatinib)
    TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (NCT01860456)
    Phase N/A
    University of Pisa
    Recruiting
    Last update posted :
    10/09/2023
    Initiation :
    05/01/2013
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib)
    Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line (NOFRETETE) (NCT05734053)
    Phase N/A
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    08/21/2023
    Initiation :
    06/28/2016
    Primary completion :
    09/08/2022
    Completion :
    09/08/2022
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib (FINESTdm) (NCT04681820)
    Phase N/A
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    08/01/2023
    Initiation :
    11/01/2020
    Primary completion :
    12/01/2023
    Completion :
    11/01/2024
    ABL1 • BCR
    |
    BCR-ABL1 V299L • BCR-ABL1 F317L • BCR-ABL1 M244V • BCR-ABL1 M351T • BCR-ABL1 H396R • BCR-ABL1 Q252H • BCR-ABL1 mutation • BCR-ABL1 E355G • BCR-ABL1 L387M • ABL1 F317L • ABL1 L387M • ABL1 M351T
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Hansoh Xinfu (flumatinib)
    Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF) (NCT04147533)
    Phase 2
    Masaryk University
    Active, not recruiting
    Last update posted :
    07/06/2023
    Initiation :
    06/16/2020
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib)
    Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01806571)
    Phase 2
    Mayo Clinic
    Completed
    Last update posted :
    05/31/2023
    Initiation :
    03/12/2015
    Primary completion :
    07/31/2017
    Completion :
    11/30/2019
    KIT
    |
    KIT expression
    |
    cytarabine • Tasigna (nilotinib) • daunorubicin • Starasid (cytarabine ocfosfate)
    Frontline Asciminib Combination in Chronic Phase CML (CMLXI) (NCT03906292)
    Phase 2
    University of Jena
    Active, not recruiting
    Last update posted :
    05/10/2023
    Initiation :
    08/19/2019
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Scemblix (asciminib)
    TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (NCT01657604)
    Phase 3
    University of Jena
    Completed
    Last update posted :
    05/10/2023
    Initiation :
    08/24/2012
    Primary completion :
    05/31/2022
    Completion :
    05/31/2022
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase (HQP1351CC203) (NCT04126681)
    Phase 2
    Ascentage Pharma Group Inc.
    Active, not recruiting
    Last update posted :
    04/04/2023
    Initiation :
    10/21/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Nailike (olverembatinib) • Synribo (omacetaxine mepesuccinate) • hydroxyurea
    A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia (NCT05743465)
    Phase N/A
    Takeda
    Completed
    Last update posted :
    03/02/2023
    Initiation :
    10/06/2021
    Primary completion :
    11/30/2022
    Completion :
    11/30/2022
    ABL1 • BCR
    |
    dasatinib • imatinib • Iclusig (ponatinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
    Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients (NCT03885830)
    Phase N/A
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    01/11/2023
    Initiation :
    06/20/2019
    Primary completion :
    06/15/2022
    Completion :
    06/15/2022
    ABL1 • BCR
    |
    dasatinib • imatinib • Tasigna (nilotinib) • Bosulif (bosutinib)
    Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study (LAL1408) (NCT01025505)
    Phase 2
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    Last update posted :
    10/11/2022
    Initiation :
    06/01/2012
    Primary completion :
    12/01/2015
    Completion :
    09/01/2020
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib)
    Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (Nilo Post-STIM) (NCT01774630)
    Phase 2
    University Hospital, Bordeaux
    Completed
    Last update posted :
    08/18/2022
    Initiation :
    04/10/2013
    Primary completion :
    12/21/2020
    Completion :
    12/21/2020
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib)
    Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR) (NCT02546674)
    Phase 4
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    07/22/2022
    Initiation :
    02/18/2016
    Primary completion :
    02/23/2021
    Completion :
    03/25/2021
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults (VINILO) (NCT01884922)
    Phase 1
    Gustave Roussy, Cancer Campus, Grand Paris
    Completed
    Last update posted :
    05/27/2022
    Initiation :
    05/29/2013
    Primary completion :
    09/02/2015
    Completion :
    04/28/2016
    NF1
    |
    Tasigna (nilotinib) • vinblastine
    KRT-232 and TKI Study in Chronic Myeloid Leukemia (KRT-232-117) (NCT04835584)
    Phase 1b/2
    Kartos Therapeutics, Inc.
    Recruiting
    Last update posted :
    03/21/2022
    Initiation :
    05/07/2021
    Primary completion :
    12/31/2024
    Completion :
    06/30/2026
    ABL1 • BCR
    |
    TP53 wild-type
    |
    dasatinib • Tasigna (nilotinib) • navtemadlin (KRT-232)
    Nilotinib for First-line Newly Diagnosed CML-CP Patients (NCT03942094)
    Phase 3
    Shenzhen Second People's Hospital
    Recruiting
    Last update posted :
    03/16/2022
    Initiation :
    06/01/2019
    Primary completion :
    06/01/2023
    Completion :
    12/01/2023
    ABL1 • BCR
    |
    Tasigna (nilotinib)
    Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes (NCT04326933)
    Phase N/A
    Assiut University
    Active, not recruiting
    Last update posted :
    02/22/2022
    Initiation :
    01/01/2020
    Primary completion :
    02/28/2022
    Completion :
    03/31/2022
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib)
    Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia (SUSTRENIM) (NCT02602314)
    Phase 4
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Active, not recruiting
    Last update posted :
    01/20/2022
    Initiation :
    11/11/2016
    Primary completion :
    02/01/2023
    Completion :
    02/01/2024
    ABL1 • BCR
    |
    imatinib • Tasigna (nilotinib)
    Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase (CML0307) (NCT00481052)
    Phase 2
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    Last update posted :
    01/18/2022
    Initiation :
    06/23/2007
    Primary completion :
    04/30/2018
    Completion :
    04/30/2018
    ABL1 • BCR
    |
    Tasigna (nilotinib)